CRMD vs PATH · P/E 3.9, rev $43.5M vs P/E 19, rev $1.61B
CorMedix Inc (CRMD) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
CorMedix Inc (CRMD) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CRMD revenue for 2024-12-31 was $43.5M. Net income was -$17.9M. Revenue was up 66363.1% from 2022-12-31 to 2024-12-31. CRMD currently screens at market cap $655.9M and trailing P/E 3.9.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CRMD currently screens at market cap $655.9M and trailing P/E 3.9. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CRMD and PATH stock pages for the full models.
Not investment advice.